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Abstract
Background: Splenectomy is associated with increased risk for bacteremia, due to impaired clearance of
bloodborne agents and to altered phagocytosis and humoral immunity. We conducted a retrospective cohort
study of patients at risk for splenectomy for a 13-year period to determine immunization coverage, and
outcomes of those with and without splenectomy, and with or without receipt of influenza or pneumococcal
vaccine.
Methods: Data were extracted from the provincial Medical Services Insurance database for insured services
rendered by a physician for 1990-2002, and from the Vital Statistics Death database. The eligible cohort was
selected based on diagnostic codes for hematologic conditions for which splenectomy might be considered, such
as immune thrombocytopenia. Each patient was followed longitudinally from the date of first diagnosis until
31Dec2002, or death, or relocation out-of province. In addition, persons with splenectomy and no hematologic
condition were identified and followed for 6 months post-surgery. Infectious illness rates per 100 person-years of
observation and death rates were calculated with and without splenectomy. Death rates were determined using
splenectomy status as a time-dependent covariate. The relationship between splenectomy and death according to
immunization status was examined using Cox proportional hazard ratios.
Results: Of 38,812 persons in the cohort 427 subjects with a hematologic diagnosis had splenectomy and another
452 subjects without a hematologic diagnosis had this surgery. 72% were > 18 years of age. Pneumococcal
immunization was recorded in 16.5% of asplenic patients overall, and was not associated with reduced risk of
death in these persons (adjusted Hazard Ratio [HR] = 1.07, 95% CI 0.70 - 1.65). Influenza immunization was
recorded in 53.1% of asplenic patients overall, and was associated with reduced risk of death (adjusted HR = 0.46,
0.33-0.62). No pneumococcal or influenza immunization was recorded in patients with a hematologic diagnosis
without splenectomy. Infectious illness visits were higher among all patients who had a splenectomy than among
those without a splenectomy (151 visits/100 person-years of observation in the post-splenectomy period vs. 120
visits/100 person-years; p < 0.0001).
Conclusions: In asplenic patients, influenza immunization is associated with a 54% reduced risk of death
compared to unimmunized asplenic persons; no reduction in risk was demonstrated with (polysaccharide)
pneumococcal vaccine. Vaccine coverage in the entire cohort was less than routinely recommended. Improved
delivery of infection prevention programs to this population is warranted. Conjugate pneumococcal vaccines
should be urgently studied in this immunocompromised population.
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Splenectomy is associated with increased risk for bacter-
emia due to impaired clearance of bloodborne agents,
and to altered phagocytosis and humoral immunity[1-4].
The spleen is also the main site of immunoglobulin M
synthesis, and low levels of the opsonins tuftsin and
properdin have been reported post-splenectomy [5]. In a
review of 78 studies with 19 680 asplenic patients, 3.2%
developed invasive infection and the overall mortality
was 1.4% [6]. For those who develop fulminant, over-
whelming post-splenectomy sepsis, mortality rates
approach 50% [7], and those who survive may be left
with significant morbidity. Streptococcus pneumoniae is
the most common etiology of serious infection in this
population[8], but illness due to other encapsulated
organisms such as Haemophilus influenzae and Neisseria
meningitidis, occurs.
Although infection prevention strategies such as
immunization, antibiotic prophylaxis and early care for
febrile illness have been recommended for asplenic
patients for decades, implementation is often not opti-
mal [8-15]. Life-threatening infectious complications of
splenectomy continue to occur. Accordingly, we
reviewed outcomes of a province-wide cohort of patients
who had health conditions for which splenectomy might
be considered or indicated over a 13-year period to
determine vaccine coverage rates, if patients with sple-
nectomy have different infection and mortality rates
than patients without splenectomy, and whether immu-
nization was associated with better outcomes.
Methods
Data sources
A population-based retrospective cohort was assembled
by linking several comprehensive provincial health data-
bases. Nova Scotia is a province in Eastern Canada with
a population of ~ 900,000. All residents have a unique
health card number which is used to track health ser-
vices in the universal health care system, to reimburse
providers and to track persons moving in and out of the
province. The cohort consisted of all persons resident in
the province from 1990-2002, who had health condi-
tions for which splenectomy might be considered or
indicated.
Data were extracted from the Nova Scotia Medical
Services Insurance (MSI) database for insured services
rendered by a physician for 1990-2002 and from the
provincial Vital Statistics Death Database. The MSI
database is a single comprehensive administrative data-
base for health services. All physicians and all residents
in the province for more than three months were parti-
cipants in the health insurance plan. Recording and
reporting of services given was the only method of
physician remuneration in this largely fee-for-service
system and regular ongoing auditing confirms services
are given. The cohort of persons at risk for splenectomy
was selected by identifying all International Classifica-
tion of Diagnostic Codes - 9
th Clinical Modification 9
(ICD-CM9) for health conditions for which splenectomy
might be considered or indicated. These codes were
grouped into five categories, and all patients with a first
field diagnostic code for at least one of the following
categories were included: immune thrombocytopenia
(ITP), Hodgkin’s disease, non-Hodgkin lymphoma, hae-
molytic anemia, or hypersplenism.
Other variables extracted included the following: birth
date, diagnosis and service(s), immunizations delivered,
whether a splenectomy was performed and the date of
surgery, physician visits for which an infectious disease
code was used ("infectious illness visit”), and, if applic-
able, moving out of the province or death. Antibiotic use
was not recorded in these datasets. Each patient was fol-
lowed from the date of first diagnosis until 31 Dec 2002,
or death, or relocation out-of province. In addition, an
extraction was completed for patients who had a sple-
nectomy during the same time period but did not have
one of the aforementioned health conditions. These
asplenic persons were assumed to have had a splenect-
omy on a non-elective basis. The codes for these concur-
rent events were diverse and included trauma and other
surgeries. An arbitrary time period of 6 months was
selected to follow health outcomes post-splenectomy.
The conjugate heptavalent pneumococcal vaccine Pre-
vnar® was brought into routine immunization programs
between 2001 and 2003 in Canada and therefore it is
assumed that the 23-valent pneumococcal polysacchar-
ide vaccine was the only pneumococcal vaccine used to
immunize the population in this study. The influenza
vaccine used in Canada is a trivalent inactivated inject-
able formulation.
Statistical analysis
The outcome measures of interest were the number of
patients living with asplenia (in order to plan health
care program delivery), the immunization history of
asplenic persons compared to those without splenect-
omy, and the incidence of infectious illness visits and
death in these high risk persons according to immuniza-
tion status and splenectomy.
Categorical and continuous variables were analyzed
using descriptive statistics. Median, 25
th and 75
th per-
centiles were used where variables were not normally
distributed. In the case of cell counts less than five, the
numbers are not reported.
Infectious illness rates were expressed per 100 person-
years of observation in persons with splenectomy and
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1,000 person years of observation, by splenectomy status
and by immunization status. The relationship between
splenectomy and death was assessed using Cox propor-
tional hazards regression models (adjusted and unad-
justed) using a time-dependent covariate approach
whereby the follow-up time for subjects with splenect-
omy is divided into pre-and post-splenectomy. The rela-
tionship between any pneumococcal or influenza
immunization and death was evaluated using standard
survival analysis among the subset of subjects who had
a splenectomy. Survival curves were adjusted for age at
diagnosis, gender and diagnostic category. The “end
date” for the study was assigned using the termination
date if the subject moved or died, or the end of the
study period (31 December 2002).
All analyses were performed using SAS (SAS Institute
Inc., Cary NC).
The study protocol was approved by the Research
Ethics Boards of the IWK Health Centre and the Capital
Health District, Halifax, Nova Scotia and by the Privacy
Officer of the Nova Scotia Department of Health.
Results
Demographics
The total cohort of patients with hematologic diagnoses
of interest and with splenectomy but no pre-existing
hematologic diagnosis consisted of 38,812 patients; 72%
were >18 years of age (n = 28,096). Females comprised
57% of the cohort (22,095/38,812). The most common
hematologic diagnosis was hypersplenism (78% of chil-
dren, 44% of adults) followed by ITP (11% of children,
23% of adults). Splenectomy occurred in 427 patients
with a hematologic diagnosis in the cohort (1.2%), and
in another 452 subjects without a hematologic diagnosis
( 4 3 1a d u l t s ;2 1c h i l d r e n ) .T h u so v e rt h e1 3y e a r s ,8 7 9
patients, or about 68 persons each year, had splenect-
omy. Characteristics of the asplenic patients are seen in
Table 1.
Splenectomy was most commonly performed for ITP
(4.04 splenectomies/1000 person years). Rates for other
hematologic conditions were hemolytic anemia (3.63/
1000 person years), Non-Hodgkins lymphoma (2.84/
1000 person-years), Hodgkin’s disease (1.32/1000 person
years) and hypersplenism (0.40/1000 person-years).
Vaccine coverage
Immunization against Streptococcus pneumoniae was
recorded in 16.5% (n = 132) of all asplenic patients, but
not recorded in any patients with a hematologic diagno-
sis without splenectomy (Figure 1). Influenza immuniza-
tion was recorded in 53.1% (467/879) of asplenic
patients, and 140 patients had at least one influenza vac-
cination, 79 had two, 62 had 3, 52 had 4, 49 had 5, 48
Table 1 Characteristics of 879 asplenic patients
Characteristic Total Pre-existing hematologic diagnosis for which splenectomy could be
considered
No pre-existing
hematologic
diagnosis
ITP Hodgkins
disease
Non-Hodgkins
lymphoma
Hemolytic
anemia
Hypersplenism
n = 879 n = 196 n = 9 n = 89 n = 55 n = 78 n = 452
(100%) (22.3%) (1.0%) (10.1%) (6.3%) (8.9%) (51.4%)
n% n% n % n % n % n % n %
Age at splenectomy
≤ 18 years 65 7.4 12 6.1 †† 19 34.6 11 14.1 21 4.7
> 18 years 814 92.6 184 93.9 36 65.4 67 85.9 431 95.3
Gender
Male 471 53.6 79 40.3 † 54 60.7 27 49.1 41 52.6 265 58.6
Female 408 46.4 117 56.7 35 39.3 28 50.9 37 47.4 187 41.4
Death
Yes 230 26.2 39 19.9 † 28 31.5 13 23.6 12 15.4 135 29.9
No 649 73.8 157 80.1 61 68.5 42 76.4 66 84.6 317 70.1
Any vaccination for influenza
Yes 467 53.1 123 62.8 † 49 55.1 39 70.9 41 52.6 210 46.5
No 412 46.9 73 37.2 40 44.9 16 29.1 37 47.4 242 53.5
Any vaccination for S.pneumoniae
Yes 145 16.5 42 21.4 † 12 13.5 16 29.1 21 26.9 53 11.7
No 734 83.5 154 78.6 77 86.5 39 70.9 57 73.1 399 88.3
ITP = immune thrombocytopenic purpura
† Numbers suppressed due to cell size < 5
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The median number of patients receiving both vaccines
was 137. Both forms of immunization were recorded
more frequently among asplenic patients with a pre-
existing hematologic condition than in those without a
pre-existing hematologic condition.
Outcomes
Infectious illness visits (IIV) were higher among all
patients who had a splenectomy than among those with-
out a splenectomy (151 visits/100 person-years of obser-
vation in the post-splenectomy period vs. 120 visits/100
person-years; p < 0.0001). Among subjects who had a
splenectomy, IIV were decreased in the period post-
splenectomy compared to the period before splenectomy
for all subgroups except among those patients with ITP.
I nt h ep e r i o db e f o r es u r g e r y ,o v e r a l lt h er a t eo fI I Vw a s
265 per 100 person years of observation, whereas post-
surgery the rate of IIV was 151 per 100 person years of
observation.
Among subjects with a hematologic condition, results
from Cox proportional hazards regression models, in
which splenectomy was modeled as a time-dependent
covariate, indicated that the risk of death was signifi-
cantly higher for patients who underwent splenectomy
compared with those who did not (Table 2).
In subgroup analysis the HR for the association
between splenectomy and death was not different for
conditions which were considered malignant (Hodgkins
disease, non-Hodgkins lymphoma) compared to those
considered non-malignant conditions (ITP, hemolytic
anemia, hypersplenism): was 1.74 (1.22-2.48). v. 1.75
(1.36-2.54).
Among asplenic subjects, pneumococcal immuniza-
tion, adjusted for age at diagnosis, gender and diagnostic
category, was associated with a reduced risk of death
when the effect of influenza vaccine was not considered
(Hazard Ratio [HR] 0.68, 95% CI 0.47-1.00). However,
no protective effect of pneumococcal vaccine was
observed when the analysis was adjusted for the effect
of influenza vaccination: HR 1.07 (95% CI 0.70-1.65).
The risk of death was reduced among those aplenic
persons who had at least one influenza vaccine: HR
(adjusted for pneumococcal vaccine) 0.46 (95% CI 0.33-
0 . 6 2 ) .I ns u b g r o u pa n a l y s i st h i se f f e c tw a ss e e ni nI T P ,
hemolytic anemia, and splenectomy without a pre-exist-
ing hematologic diagnosis, but not in the other groups
(Table 3).
The hazard ratio for the association between influenza
immunization and death for the non-malignant group is
0.35 (0.21-0.58) and for the malignant subgroup is 0.48
(0.22-1.04). For pneumococcal immunization these HRs
are 0.32 (0.17-0.58) in the non-malignant subgroup and
0.49 (0.22-1.10) for the malignant group.
Figure 2 presents the survival curve of the relationship
between death and influenza immunization in immu-
nized and unimmunized persons with splenectomy and
any hematologic condition.
Discussion
This study shows a 53% reduced risk of death in asple-
nic persons who received influenza immunization
Figure 1 Percentage of patients with immunization according to splenectomy status, Province of NS 1990-2002.H D=H e m a t o l o g i c
disorder.
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zation; but surprisingly no influence on death was seen
for pneumococcal immunization. Overwhelming post-
splenectomy infection (OPSI), usually due to Streptococ-
cus pneumoniae, is perhaps the best known infectious
complication of asplenia and thus pneumococcal immu-
nization is universally recommended. Immunization
against other encapsulated organisms such as H. influen-
zae and Neisseria meningitidis is also recommended,
preferably at least two weeks prior to splenectomy.
Annual influenza vaccine, as well as age appropriate
immunization, is also considered standard of care.
Receipt of influenza vaccine was associated with
reduced risk of death in the whole cohort and in three
subgroups (asplenic patients without a hematologic con-
dition, with ITP and with hemolytic anemia). The
mechanism of this protection is not clear, and no
randomized controlled trials of influenza vaccine efficacy
in asplenic persons have been performed. Asplenic per-
s o n sa r en o tg e n e r a l l yt h o u g h tt ob ea ti n c r e a s e dr i s k
for complicated viral infections, since innate and cell-
mediated immunity are intact. However, production of
antibody involves interaction between the humoral and
cell-mediated immune systems which could be altered
in asplenic persons, and cases of serious viral infection
in asplenic persons have been reported[16]. The associa-
tion between influenza infection and secondary bacterial
pneumonia is established; this may be the mechanism
by which influenza vaccine protects asplenic persons.
This protection, if real, is not well studied in this immu-
nocompromised population. Indeed, a Medline search
using the MESH terms “influenza vaccines” AND “sple-
nectomy” or “spleen (subheading abnormalities)” back to
1966 revealed many guidelines, but only one human
Table 2 Hazards ratios (HR) and 95% confidence intervals (CI) for the relationship between splenectomy (Vs. no
splenectomy) and death among subjects with a hematologic condition*
Diagnosis category Death rates (per 1000 person-years) HR, 95% CI
†
Splenectomy No splenectomy
ITP 36.28 26.21 1.57, 1.08-2.29
Hodgkins disease 57.98 26.61 6.47, 2.83-14.81
Non-Hodgkins lymphoma 75.30 56.29 1.58, 1.05-2.39
Hemolytic anemia 45.18 21.80 3.40, 1.76-6.57
Hypersplenism 19.68 5.05 1.16, 0.59-2.26
Overall (all patients with a hematologic condition) ‡ 39.65 15.34 1.75, 1.37-2.24
ITP = immune thrombocytopenic purpura
* Rates and HR calculated using the time-dependent covariate approach where follow-up time for subjects with splenectomy is divided into pre- and post-
splenectomy
† Adjusted for age at diagnosis and gender.
‡ Adjusted for age at diagnosis, gender and diagnostic category.
Table 3 Deaths rates and hazard ratios (HR) with 95% confidence intervals (CI) for the independent relationship
between pneumococcal vaccination (vs. no pneumococcal vaccination), and influenza vaccination (vs. no influenza
vaccination) and death among asplenic subjects
Diagnosis category Pneumococcal vaccination Influenza vaccination
Death rates (per 1000 person-years) HR, 95% CI* Death rates (per 1000 person-
years)
HR, 95% CI*
Pneumococcal
vaccination
No pneumococcal
vaccination
Influenza
vaccination
No influenza
vaccination
ITP 16.80 32.35 0.91, 0.33-2.54 16.00 52.79 0.36, 0.18-0.74
Hodgkins disease 0.00 53.50 Indeterminate 23.97 74.21 indeterminate
Non-Hodgkins lymphoma 45.77 59.02 1.00, 0.32-3.09 42.59 75.37 0.45, 0.19-1.08
Hemolytic anemia 25.10 38.78 1.89, 0.31-11.44 17.65 84.98 0.10, 0.12-0.55
Hypersplenism 15.77 18.16 3.21, 0.32-32.13 10.16 27.37 0.17, 0.02-1.38
Splenectomy, no pre-existing
hematologic diagnosis
41.81 57.21 1.11, 0.61-2.01 39.58 68.43 0.52, 0.34-0.78
Overall (all asplenic patients)
† 28.44 45.78 1.07, 0.70-1.65 27.00 61.67 0.46, 0.33-0.62
ITP = immune thrombocytopenic purpura
* Adjusted for age at diagnosis and gender.
† Adjusted for age at diagnosis, gender and diagnostic category.
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[17], one in persons with Hodgkin’s disease[18] and a
letter to the editor[19]. In 62 patients with splenectomy
compared to 55 healthy controls, serologic responses
met regulatory criteria regardless of the time from sple-
nectomy, with seroprotection outcomes ranging from
62.9 to 90.3%. Our finding of the protective effect of
influenza vaccine could be important for improved
health for asplenic and hyposplenic persons, and should
be confirmed in other studies.
Immunization coverage overall was very low for
(16.5% for S. pneumoniae) but better for influenza
(53.1%). It is unlikely that our finding of poor immuni-
zation coverage is restricted to our jurisdiction, as others
have noted incomplete physician and patient knowledge
of risks and preventive interventions, poor vaccine cov-
erage, and a lack of systematic immunization programs
[9-15,20]. If influenza vaccine offers the protection
observed in this study, the need for improved delivery of
vaccine will be necessary.
T h e r ei sc o n c e r nt h a ta s p l e n i cp e r s o n sm a yd e m o n -
strate reduced immunogenicity to vaccines. In a few
small studies variable immunogenicity has been demon-
strated for polysaccharide vaccines [21-23], but better
immune responses were seen for protein conjugate vac-
cines [24-28]. The pneumococcal polysaccharide vaccine
was in use during the time period of the study. The
ongoing introduction of highly effective and immuno-
genic protein conjugate vaccines for H. influenzae, S.
pneumoniae and N. meningitides has the potential to
offer asplenic persons both direct and indirect protection
from life-threatening infection. Indirect protection of
unimmunized older persons against invasive pneumococ-
cal disease has been shown following the introduction of
universal infant immunization with heptavalent protein
conjugate S. pneumoniae vaccine [29,30]. Little effort has
been directed towards investigation of how these vaccines
could be best used in asplenic person in order to deter-
mine optimum schedules, doses and timing of immuniza-
tion, and we suggest that it is urgently needed.
There are several limitations to the design of this
study. Because health-care utilization data was collected
if a patient sought care, patients with health-seeking
behaviour may be more likely to be identified with this
method than in a prospective study where active surveil-
lance could be performed. However, it should be noted
that this would be unlikely to preferentially favor influ-
enza over pneumococcal immunization. As well one of
our outcomes was death as determined by a governmen-
tal Vital Statistics database, which would not have been
subject to any biases. Comprehensive risk factor infor-
mation is not collected in these datasets and so there
may be confounders for splenectomy, physician visits,
death and for immunization which could contribute to
outcomes but are not controlled for in the analysis. For
example, prophylactic antibiotic use, recommended by
many authorities for up to five years to life after sple-
nectomy, may be more common in patients who receive
immunization from their care providers. Of note, we did
control for age at diagnosis, sex, hematologic condition,
time since diagnosis and splenectomy status. A further
limitation is short follow-up for after splenectomy for
persons without hematologic conditions; future studies
should ensure follow-up of several years. Finally, this
population likely underestimates the burden of infection
in asplenic persons, since those with functional asplenia,
hyposplenia or congenital asplenia would not have been
identified.
Figure 2 Age and sex-adjusted survival curves for persons with a splenectomy and any hematologic condition, with and without
influenza vaccination. Y axis = Probability of surviving, X axis = years after splenectomy
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tions are recommended to avoid devastating and life-
threatening complications of infection in persons with
splenectomy [3,31]. These include early medical attention
and antibiotic therapy for infectious illness, antibiotic
prophylaxis, patient education about risks associated with
infection, travel and animal bites, and wearing an alert
bracelet, pendant or card, so that health professionals
will be aware of their status. The literature is replete with
surveys showing that recommendations for the preven-
tion of infection are often not being followed by health
care providers and patients, and that many asplenic
patients are not aware of the risk associated with their
acquired immunodeficiency [8,9,12,20,32,10,11,15]. An
ideal system to ensure compliance with guidelines has
not been reported, but a post-splenectomy registry may
p r o v i d eas y s t e m a t i ca p p r o a c ht ot h i sp o p u l a t i o n ,a n d
could be cost-effective in terms of avoidance of mortality
and overwhelming post-splenectomy sepsis [33]. Based
on the results of this study, we plan to develop a method
for contacting asplenic persons in our province to deter-
mine their health education needs, and their willingness
to join a registry so that appropriate immunization and
other interventions can be offered over time.
Conclusions
In a retrospective population-based cohort study from
1990-2002 of persons with splenectomy, influenza
immunization was associated with a 54% reduced risk of
death compared to unimmunized asplenic persons. No
reduction in risk of death was demonstrated with pneu-
mococcal vaccine. Vaccine coverage for both pneumo-
coccal and influenza vaccines in the entire cohort was
less than routinely recommended (16.5% and 53.1%
respectively). Improved delivery of infection prevention
programs to this population is warranted. Conjugate
pneumococcal vaccines should be urgently studied in
this immunocompromised population.
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